

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE YEAR ENDED DECEMBER 31, 2023**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2023, and the comparative figures as set out below.

	<b>For the period from January 1 to December 31</b>		
	<b>2023</b>	<b>2022</b>	<b>Change</b>
	<b>RMB'million</b>	<b>RMB'million</b>	<b>%</b>
Revenue	<b>Approximately 430.0–450.0</b>	250.8	<b>Approximately 71.5–79.4</b>

The increase in revenue was primarily attributable to the following reasons:

- (i) the commercialization of transcatheter aortic valve replacement products (including the first-generation product TaurusOne<sup>®</sup> and second-generation retrievable product TaurusElite<sup>®</sup>), was accelerated, further increasing the Group's market share;
- (ii) the Group's existing neurointerventional products (including Tethys<sup>®</sup> Intermediate Catheter, Jasper<sup>®</sup> Detachable Coil, and SacSpeed<sup>®</sup> Balloon Dilatation Catheter, etc.) continued to gain market share with significant sales volume growth; and
- (iii) the Group's ischemic and vascular access products (including Syphonet<sup>®</sup> Stent Retriever, Fastunnel<sup>®</sup> Delivery Balloon Dilatation Catheter, Tethys AS<sup>®</sup> Aspiration Catheter, DCwire<sup>™</sup> Micro Guidewire and Fluxcap<sup>®</sup> Balloon Guide Catheter), which were newly approved in 2022 and 2023, were gradually admitted by more hospitals, hence creating new revenue streams.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the year ended December 31, 2023. The above operating information is preliminary unaudited information that has not been reviewed, confirmed or audited by the auditors of the Company, nor reviewed by the audit committee of the Board, and is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the year ended December 31, 2023, which is expected to be published in March 2024 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, January 25, 2024

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.*